AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Immunology Bet

What happened

AbbVie entered into a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, acquiring all outstanding shares at $135.11 per share in cash. The acquisition brings Apogee's entire clinical-stage immunology pipeline under AbbVie's ownership, including the lead asset zumilokibart, a novel anti-IL-13 monoclonal antibody with an extended half-life designed for quarterly or biannual maintenance dosing. Zumilokibart is expected to enter a Phase III trial in atopic dermatitis (AD) in the second half of 2026, with additional trials in asthma and eosinophilic oesophagitis planned for 2026 and 2027. The pipeline also includes combination therapies APG279 (zumilokibart plus OX40 ligand binding for AD) and APG273 (zumilokibart plus TSLP inhibitor for asthma and COPD). The boards of both companies have approved the transaction, which is expected to close in Q3 2026 following shareholder and regulatory approvals.

Why it matters

This acquisition positions AbbVie to strengthen its leadership in the immunology space, a franchise built on blockbusters like Skyrizi (risankizumab), Rinvoq (upadacitinib), and Humira (adalimumab). Zumilokibart's differentiated profile - combining long-acting efficacy with strong clinical promise in atopic dermatitis - offers what AbbVie describes as mega-blockbuster peak sales potential and a best-in-category opportunity. The extended dosing schedule (two to four times per year) could differentiate zumilokibart from existing therapies by offering comparable efficacy with improved convenience. Early studies suggest the drug could deliver skin and itch relief comparable to current AD treatments. For AbbVie, the deal represents a significant capital allocation toward pipeline expansion in immunology and respiratory care, areas of high unmet patient need and sustained commercial interest.

Bigger picture

The Apogee acquisition reflects a broader trend of large pharmaceutical companies investing heavily in immunology and inflammatory disease franchises. Recent high-profile deals in the space include Biogen's acquisition of RayThera, Eli Lilly's development collaboration with Innovent Biologics, and GSK's takeover of RAPT Therapeutics. Immunology has emerged as a focal point for big pharma dealmaking, driven by the commercial success of blockbuster therapies like AbbVie's Skyrizi and Johnson & Johnson's Stelara (ustekinumab). The AbbVie–Apogee transaction is one of the larger biotech buyouts in 2025, a year that has already seen more blockbuster acquisitions than the entirety of 2024. Several major pharma companies face patent cliffs for top-selling drugs in the coming years, intensifying the search for pipeline replacements and next-generation therapies. The deal also aligns with AbbVie's broader capital commitment: the company previously announced plans to invest over $100 billion in U.S. R&D and capital investments over the next decade, including more than $10 billion in domestic manufacturing.

What to watch

Investors will monitor progress on the Phase III trial for zumilokibart in atopic dermatitis, expected to begin in the second half of 2026. Data from this pivotal study will be critical to assessing the drug's commercial viability and positioning against existing therapies. Additional trials in asthma (2026) and eosinophilic oesophagitis (2027) will help define zumilokibart's broader market opportunity. The transaction itself requires shareholder and regulatory approvals, with closure anticipated in Q3 2026. Investors should also track AbbVie's integration of Apogee's pipeline and any updates on the development timelines for combination therapies APG279 and APG273. Broader sector dynamics, including competitive immunology programs from peers and any shifts in the dealmaking environment, will provide context for AbbVie's strategic positioning in inflammatory disease.